Scarica l'app Stockscreener
0.00
100.00%
-31.49
Dopo l'orario di chiusura:
31.48
31.48
+
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CPRX Giù?
Forum
Previsione
Catalyst Pharmaceuticals Inc Borsa (CPRX) Ultime notizie
Catalyst Pharmaceuticals, Inc. Revenue Breakdown – LS:A0LCUL - TradingView
CPRX|Catalyst Pharmaceuticals Inc|Price:31.490| - TradingKey
TradingKey - TradingKey
Catalyst Pharmaceuticals | 8-K/A: Current report (Amendment) - Moomoo
Catalyst Pharmaceuticals stock steadies as investors weigh latest earnings momentum - AD HOC NEWS
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) leaves Nasdaq after cash reserves reduce deal multiple - TechStock²
Catalyst Pharmaceuticals (NASDAQ:CPRX) departs Nasdaq as merger spread narrows to one cent - TechStock²
Catalyst Pharmaceuticals CLO Brian Elsbernd Sells 242,501 Shares Amid Angelini Pharma Acquisition Completion - Kalkine Media
Catalyst Pharmaceuticals (CPRX) director’s RSUs and options cashed out in merger - Stock Titan
Catalyst Pharmaceuticals (NASDAQ: CPRX) HR chief equity cashed out at $31.50 - Stock Titan
Catalyst Pharmaceuticals (NASDAQ: CPRX) director equity converted to cash at $31.50 - Stock Titan
Angelini deal converts CATALYST PHARMACEUTICALS (NASDAQ: CPRX) officer equity to cash - Stock Titan
Catalyst Pharmaceuticals (CPRX) CCO exits equity in Angelini merger - Stock Titan
Catalyst Pharmaceuticals (CPRX) CEO equity converted to cash at $31.50 merger price - Stock Titan
Catalyst Pharmaceuticals (CPRX) CMO equity awards canceled for cash in Angelini merger - Stock Titan
Catalyst Pharmaceuticals (CPRX) CFO equity cancelled for cash in acquisition - Stock Titan
Catalyst Pharmaceuticals (CPRX) director’s RSUs and options cancelled in merger - Stock Titan
CATALYST PHARMACEUTICALS, INC. SEC Filing (Jul 17, 2026) - Stock Titan
Catalyst Pharmaceuticals, Inc. Files 8-K: Merger Agreement Details, Corporate Information & XBRL Data (2026) - Minichart
Angelini Pharma completes $4.1 billion Catalyst acquisition By Investing.com - Investing.com Australia
Italy’s Angelini Pharma completes $4.1 billion state-backed takeover of Catalyst - 1470 & 100.3 WMBD
Italy's Angelini Pharma completes $4.1 billion state-backed takeover of Catalyst - Reuters
CATALYST PHARMACEUTICALS, INC. SEC Filing (Jul 15, 2026) - Stock Titan
Catalyst Pharmaceuticals Announced Transfer or Voluntary Withdrawal of Listing - TradingView
Angelini Pharma completes $4.1 billion Catalyst acquisition - Investing.com
Angelini Pharma Completes Acquisition of Catalyst Pharmaceuticals - NTB Kommunikasjon
Angelini wraps $4.1 billion buyout of Catalyst Pharmaceuticals (NASDAQ:CPRX) at 9x projected 2026 EBITDA - TechStock²
Nasdaq moves to delist Catalyst Pharmaceuticals (Nasdaq: CPRX) common stock - Stock Titan
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) Shows Strong Growth and a High-Quality Technical Breakout Setup - ChartMill
Catalyst Pharmaceuticals, Inc.(NasdaqCM: CPRX) dropped from S&P 1000 - marketscreener.com
Catalyst Pharmaceuticals, Inc.(NasdaqCM: CPRX) dropped from S&P 600 Health Care - marketscreener.com
Catalyst Pharmaceuticals, Inc.(NasdaqCM: CPRX) dropped from S&P Composite 1500 - marketscreener.com
Catalyst Pharmaceuticals, Inc.(NasdaqCM: CPRX) dropped from S&P 600 - marketscreener.com
Catalyst Pharmaceuticals, Inc.(NasdaqCM:CPRX) dropped from S&P Biotechnology Select Industry Index - marketscreener.com
Catalyst Pharmaceuticals, Inc.(NasdaqCM: CPRX) dropped from S&P TMI Index - marketscreener.com
Catalyst Pharmaceuticals, Inc.(NasdaqCM: CPRX) dropped from S&P Global BMI Index - marketscreener.com
Angelini Pharma S.p.a. completed the acquisition of Catalyst Pharmaceuticals, Inc. from a group of shareholders. - marketscreener.com
Catalyst Pharmaceuticals (CPRX) Could Be 60% Undervalued As Merger Approval Reshapes The Board - Sahm
Catalyst Pharmaceuticals, Inc.(NasdaqCM:CPRX) dropped from Russell 3000E Growth Benchmark - marketscreener.com
Catalyst Pharmaceuticals (CPRX) Holds Steady Near Support as Consolidation PersistsBearish Pattern Stocks - Bölüm Sonu Canavarı
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX): A Textbook GARP Stock Delivering Affordable Growth - ChartMill
Catalyst Pharmaceuticals Stockholders Clear Angelini Pharma Merger - Yahoo Finance
Solaris Energy replaces Catalyst Pharmaceuticals in S&P SmallCap 600 as acquisition nears completion - Pluang
Solaris Energy Infrastructure Set to Join S&P SmallCap 600 - Yahoo Finance
Catalyst Pharmaceuticals (CPRX) Proxy filing Summary - Quartr
Catalyst Pharmaceuticals (CPRX) Q1 2025 earnings summary - Quartr
Catalyst (CPRX) up 0.6% since last earnings report: Can it continue? - MSN
Catalyst Pharma Shareholders Approve Angelini Merger Agreement - TipRanks
Catalyst Pharmaceuticals (NASDAQ: CPRX) investors back Angelini Pharma merger deal - Stock Titan
Catalyst Pharmaceuticals (CPRX) EGM 2026 Summary - Quartr
Catalyst Pharmaceuticals focuses on rare neuromuscular diseases as a specialized Nasdaq biotech - ad-hoc-news.de
Catalyst Pharmaceuticals (CPRX) Stock Looks Fairly Valued After Phase 1 Agamree Data - Sahm
Angelini Pharma to acquire Catalyst Pharmaceuticals for $4.1bn - Investing.com
Tranche Update on Catalyst Pharmaceuticals, Inc.'s Equity Buyback Plan announced on October 1, 2025. - marketscreener.com
CPRX Should I Buy - Intellectia AI
CPRX's Agamree Shows Potential Beyond DMD After Positive Phase I Data - The Globe and Mail
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX): A Deep Value Play with Rare Disease Pipeline Strength - ChartMill
CPRXCatalyst Pharmaceuticals Inc Earnings - Finviz
Santhera Notes Topline Results from Catalyst Pharmaceuticals’ Phase 1 Clinical Study of AGAMREE® - GlobeNewswire
Vamorolone Phase 1 results at Catalyst (NASDAQ: CPRX) show activity without key immunosuppression - Stock Titan
Catalyst reports Phase 1 vamorolone study results - Investing.com
Vamorolone Demonstrates On-Target Glucocorticoid Activity Without the Immunosuppression Characteristic of Traditional Corticosteroids at Clinical Doses - The Manila Times
Catalyst reports Phase 1 vamorolone study results By Investing.com - Investing.com Canada
Vamorolone Demonstrates On-Target Glucocorticoid Activity - GlobeNewswire
1.97%
0.83%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):